Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis.
暂无分享,去创建一个
David J Murphy | Eddy Fan | E. Fan | M. Pitz | M Bradley Drummond | M. Drummond | Elliott C Dasenbrook | Marshall W Pitz | E. Dasenbrook | B. Drummond | D. J. Murphy
[1] T. Seemungal,et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.
[2] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[3] Melonie P. Heron,et al. Deaths: leading causes for 2003. , 2007, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[4] I. Olkin,et al. Improving the quality of reports of meta‐analyses of randomised controlled trials: the QUOROM statement , 2000, Revista espanola de salud publica.
[5] M Cazzola,et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. , 2008, Revista portuguesa de pneumologia.
[6] Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. , 1980, Annals of internal medicine.
[7] J. Connett,et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.
[8] Cotes Je,et al. LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMA Report of the Medical Research Council Working Party , 1981, The Lancet.
[9] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[10] T. Wilt,et al. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). , 2005, Evidence report/technology assessment.
[11] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[12] M. Woodhead. Inhaled corticosteroids cause pneumonia ...or do they? , 2007, American journal of respiratory and critical care medicine.
[13] D. Postma,et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.
[14] D. Wyss,et al. Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation , 2007, British journal of pharmacology.
[15] A. Sharafkhaneh,et al. Update on the pharmacologic therapy for chronic obstructive pulmonary disease. , 2007, Clinics in chest medicine.
[16] N. Zhong,et al. The Efficacy and Safety of Combination Salmeterol (50 μg)/Fluticasone Propionate (500 μg) Inhalation Twice Daily Via Accuhaler in Chinese Patients With COPD , 2007 .
[17] S. Suissa. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs. , 2008, American journal of respiratory and critical care medicine.
[18] T. Lasserson,et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[19] M. Weatherall,et al. Dose–response relationship for risk of non‐vertebral fracture with inhaled corticosteroids , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[20] A. Anzueto,et al. COPD is associated with increased mortality in patients with community-acquired pneumonia , 2006, European Respiratory Journal.
[21] P. Lange,et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.
[22] N. Anthonisen,et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial , 2005 .
[23] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[24] A. Gonzalez,et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. , 2007, American journal of respiratory and critical care medicine.
[25] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[26] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[27] L. Boulet,et al. Ambulatory use of inhaled beta(2)-agonists for the treatment of asthma in Quebec : a population-based utilization review. , 2001, Chest.
[28] H. Nelson,et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. , 2003, The Journal of allergy and clinical immunology.
[29] M. Cazzola,et al. To add, or not to add an inhaled corticosteroid in moderate COPD: that is the question. , 2008, Chest.
[30] R. Hubbard,et al. Use of inhaled corticosteroids and the risk of fracture. , 2006, Chest.
[31] I. Olkin,et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.
[32] L. Mcgarvey,et al. Inflammation in chronic obstructive pulmonary disease: implications for new treatment strategies. , 2007, Current medicinal chemistry.
[33] D. Sin,et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[34] C. Vogelmeier,et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[35] A. Jemal,et al. Trends in the leading causes of death in the United States, 1970-2002. , 2005, JAMA.
[36] T. Lasserson,et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[37] Gil C Grimes,et al. Medications for COPD: a review of effectiveness. , 2007, American family physician.
[38] N. Zhong,et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. , 2007, Chest.
[39] K. Lohr,et al. Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes , 2006, The Annals of Family Medicine.
[40] W. MacNee,et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.
[41] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[42] D. Postma,et al. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking , 1999 .
[43] M. O. Turner. Inhaled corticosteroids and pneumonia in COPD: an association looking for evidence. , 2008, American journal of respiratory and critical care medicine.
[44] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[45] R. Hubbard,et al. Inhaled corticosteroids and the risk of fracture in chronic obstructive pulmonary disease. , 2007, QJM : monthly journal of the Association of Physicians.
[46] D. Altman,et al. Assessing Risk of Bias in Included Studies , 2008 .
[47] J. Rello,et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia , 2006, European Respiratory Journal.